Aggredyne Increases IP Portfolio to Four Patents

HOUSTON -- (BUSINESS WIRE) -- Aggredyne, Inc., a Houston-based biomedical diagnostics company that is defining a new standard for platelet function, has added a fourth patent to its intellectual property portfolio. The new patent, "Systems for Measuring Properties of a Physiologic Fluid Suspension," provides the foundation to expand the AggreGuide^TM platform to other coagulation tests, including heparin, Coumadin® (warfarin) and collagen.

"Aggredyne developed its system to be expandable, and this patent allows us to move beyond platelets into the full arena of coagulation testing," said Chairman & CEO Edward R. Teitel, MD, JD. "For the patient, it will mean only one tube of blood; for the clinic, one countertop instrument instead of two or more. For our shareholders, it means Aggredyne can broaden beyond a single product and expand testing in areas related to the effectiveness of physician-prescribed medications."

About Aggredyne’s new distributor network

With its CE Mark in place, Aggredyne is identifying high-quality international distributors to roll out its platelet function analyzers worldwide. The company recently signed an exclusive distribution agreement with NODIA for the Benelux (Belgium, The Netherlands and Luxembourg). It also signed or is completing distributor agreements in Turkey, Egypt, Israel, Greece/Cyprus, India and Scandinavia and is negotiating with distributors in several other countries.

“In building a strong distributor network, we are focusing initially on areas that can use our inexpensive, single-channel AggreGuide A-100, but will be expandable to our fully automated, multi-test instrument, the A-600,” reported Todd Kronshage, executive vice president of sales and marketing.

ABOUT AGGREDYNE, INC.

Aggredyne, Inc. (www.aggredyne.com) is a biomedical company founded in 2011 to commercialize the AggreGuide^TM platelet function analyzer. The AggreGuide system is an in-vitro diagnostic test that measures how sticky a patient’s platelets are and how well the patient is responding to antiplatelet medications such as aspirin, Plavix® (clopidogrel), Effient® (prasugrel) and Brilinta® (ticagrelor).

Registered trademarks: Coumadin (Bristol-Myers Squibb), Plavix (Sanofi), Effient (Eli Lilly and Company), Brilinta (AstraZeneca group of companies).

SAFE HARBOR STATEMENT

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements regarding Aggredyne’s business that are not historical facts are “forward-looking statements,” which involve risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements.